Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study"

Circulation. 2023 Sep 26;148(13):1057. doi: 10.1161/CIRCULATIONAHA.123.065198. Epub 2023 Sep 25.

Authors

Jairo Aldana-Bitar^{1

2}, Ronald P Karlsberg², Matthew J Budoff¹

Affiliations

¹ The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles Medical Center (J.A-B., M.J.B.).
² Cardiovascular Research Foundation of Southern California, Beverly Hills (J.A-B., R.P.K.).

PMID: 37747953
DOI: 10.1161/CIRCULATIONAHA.123.065198

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Coronary Artery Disease*
Humans
Hyperlipoproteinemia Type II* / complications
Hyperlipoproteinemia Type II* / diagnosis
Hyperlipoproteinemia Type II* / genetics

Substances

alirocumab
Antibodies, Monoclonal, Humanized